For a better experience of our website please update you web browser from IE11 to Microsoft Edge or an alternative modern browser such as Google Chrome. Thank you.

Your partner in science for end-to-end CRDMO solutions

Read the latest press releases from Jubilant Biosys in the developments within the broad spectrum of CRO chemistry services, as well as our recent collaborative programs with leading global healthcare companies. 

Our flexible approach helps clients understand more about our role in improving the quality of our discovery informatics, structural biology, medicinal chemistry, drug discovery services, in-vitro models and translational sciences. 

pdf icon

11th November 2021

Jubilant Biosys Limited Announces New Chemistry Innovation Research Center to Support Expanded Discovery Chemistry and in-vitro ADME Services for Clients like Turning Point Therapeutics.

Jubilant Biosys Limited announced today, an expansion of its facilities to support its discovery chemistry and in-vitro ADME Service offerings.

pdf icon

7th September 2021

Jubilant Biosys Limited announces the appointment of Mr. Giuliano Perfetti as Chief Executive Officer

Jubilant Biosys Limited announces the appointment of Mr. Giuliano Perfetti as Chief Executive Officer

pdf icon

9th February 2021

Jubilant Biosys and Yale University announce collaboration

New Haven, CT. & Bengaluru, India—Today, Jubilant Biosys and Yale University have announced a research collaboration for multiple small molecule research programs.

pdf icon

28th July 2020

Jubilant Biosys Limited Announces The Merger With Jubilant Chemsys Limited

Jubilant Biosys Limited (“Biosys”), a wholly owned subsidiary of Jubilant Life Sciences Limited, today announced completion of the merger with its sister company Jubilant Chemsys Limited, based in Noida, India. The combined entities will now operate as Jubilant Biosys...

pdf icon

13th May 2020

Jubilant Life Sciences grants an exclusive license to Lengo Therapeutics to Discover and Develop Oncology Medicines

“Company formation is one of our core activities at Frazier, and Jubilant has been a key part of several of our early-stage companies” Daniel Estes, Ph.D., General Partner on the Frazier Life Sciences team.

PDF Icon

28th Nov 2019

Jubilant Biosys Commences Major Capacity Expansions For Its Drug Discovery Services Business

Due to growing customer demand for its range of functional and integrated drug discovery services, Jubilant Biosys has started the design and construction of a brand new state-of-the-art chemistry services laboratories on the existing Jubilant Greater Noida site.

PDF Icon

8th May 2019

Jubilant Biosys Selects CDD Vault for Discovery Research Informatics

Jubilant Biosys and Collaborative Drug Discovery (CDD) announced today, following an exhaustive evaluation, Jubilant has chosen CDD Vault as their discovery research informatics platform for the next 5 years.

PDF Icon

28th March 2019

Jubilant Biosys is First to add ForteBio’s latest SPR System in India

Jubilant Biosys announced today that it has added advanced Pioneer FE system to its platform of drug discovery solutions available to customers. The Pioneer FE system from ForteBio represents the next generation SPR instrumentation for label-free characterization of biomolecules.

PDF Icon

13th February 2019

Jubilant Biosys expands collaboration with Sanofi in CNS Therapeutic Area

Collaboration aimed at discovery of small molecule inhibitors targeting neurological disorders.

PDF Icon

29th November 2017

Jubilant Biosys Announces Early Milestone in Collaborative Discovery Program

Jubilant Biosys announced today that they successfully achieved an early stage milestone related to a collaborative program with Sanofi in Frankfurt, Germany focused on metabolic disorders.

PDF Icon

19th September 2016

Jubilant Biosys Strengthens its Leadership Team with Two Key Appointments

Jubilant Biosys Ltd announced two new leadership appointments. Mr. Steven Hutchins has been appointed as President and Dr. Takeshi Yura has been appointed as Vice President of Medicinal Chemistry.

PDF Icon

7th Jan 2016

Jubilant Biosys and Sanofi Deutschland GmbH enter into a Strategic Alliance

Collaboration aimed at discovery and development of small molecule inhibitors through to Phase I proof of mechanism in metabolic disorders therapeutic area.